Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will CE report Q1 2026 free cash flow below $130M?
Current Prediction
Why This Question Matters
Q1 2026 FCF is the first survival data point for the recovery thesis. CE guided FY2026 FCF to $650-750M with the Q1 historical pattern running 15-20% of full-year. A sub-$130M Q1 print would invalidate the run-rate math behind the FY guide and push FUNDING_FRAGILITY toward STRAINED. A clean print at or above $130M would validate the survival math and de-escalate stress-scanner concerns. This market directly tests the load-bearing $700M FY2025 actual / $650-750M FY2026 guide that anchors four lens assessments.
Prediction Distribution
Individual Predictions(9 runs)
Q1 chemicals seasonality runs 15-20% of FY FCF — at the $650M low end of guide that's $98-130M; at $700M (FY2025 actual run-rate) it's $105-140M. China JV dividend timing pushed post-Q1-audit deducts ~$50-100M from Q1 receipts vs prior pattern. That alone moves the central case toward sub-$130M. Mgmt has executed FCF discipline (CapEx maintenance, working capital release), so absolute floor probably ~$80-100M. The threshold ($130M) sits right at the natural Q1 seasonal cluster. Probability ~30-35%.
Triangulating: $700M FY2025 with Q1 typically lowest; FY2026 guide $650-750M slightly weaker. Q1 2026 expectation $100-150M base case. The $130M threshold is roughly central. Working capital direction ambiguous — could go either way ±$50M. Methanol input cost stable. Auto/durables Q1 weak per mgmt commentary. Net: ~28-32% probability of sub-$130M print.
Mgmt has strong incentive to deliver Q1 in line — narrative protection post-Citi rally. Even if China JV timing pushes receipts, working capital release can backfill. Counter-argument: chemicals Q1 seasonality is real and CE has no recent track record of upside surprise. Bias slightly below 30% given mgmt narrative pressure to deliver. ~28%.
Three concerns push probability higher: (1) Q1 always weakest quarter; (2) China JV dividend timing change is well-documented headwind; (3) mgmt acknowledged 'demand backdrop is certainly not where we were' on Q4 2025 call — Q1 reflects this directly. Counter: working capital release can buffer; mgmt has track record of FCF discipline. ~32-37% range; pick 35%.
Base rate: cyclical chemicals Q1 FCF below 20% of guide low-end happens ~30% of time. CE-specific: mgmt FCF discipline strong, narrative protection incentive high. Net 30%.
Q1 2026 expectation: $100-145M central range. Threshold $130M sits at ~70th percentile of range. Probability of falling below = 30-35%. Slight lean toward 32% given JV timing skew.
Q1 weakest quarter. China JV timing headwind. Mgmt discipline offset. ~30%.
FCF guide $650-750M. Q1 typical 15-20%. Threshold $130M = ~18% of low guide. Roughly central. ~32%.
Mgmt narrative protection + FCF discipline. Q1 typical pattern but mgmt likely overdelivers post-Citi rally. ~28%.
Resolution Criteria
Resolves YES if CE's Q1 2026 earnings release or 10-Q filing discloses free cash flow (operating cash flow minus capital expenditures, as defined in CE's earnings disclosures) below $130M. Resolves NO if Q1 2026 FCF is at or above $130M.
Resolution Source
CE Q1 2026 earnings release, earnings call slides, and 10-Q filing
Source Trigger
Quarterly FCF <$130M any quarter
Full multi-lens equity analysis